ACURATE neo2 versus SAPIEN 3 Ultra for transcatheter aortic valve implantation.

ABSTRACT:

Background

No comparative data exist with the latest generation self-expanding ACURATE neo2 (Neo2) and the balloon-expandable SAPIEN 3 Ultra (Ultra) transcatheter heart valves (THV).

Aims

We aimed to compare the outcomes after transcatheter aortic valve implantation (TAVI) using the Neo2 and the Ultra THV.

Methods

A total of 1,356 patients at 4 centres were treated either with the Neo2 (n=608) or the Ultra (n=748). The primary endpoint was device success according to the latest Valve Academic Research Consortium definitions. The association of the THV used and the primary endpoint was assessed using inverse probability treatment weighting (IPTW) and 1:1 propensity score matching (PSM), which identified 472 matched pairs.  Results: After PSM, there were no relevant dif

SUBMITTER: Pellegrini C 

PROVIDER: S-EPMC9853033 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature